Extract Value from Natural and Chemically Modified Compounds
Pre-clinical portfolio of microbiome-derived immune-modulating peptides and other small molecules with exclusive technologies and the scientific expertise for discovering, expanding and advancing a valuable
IO/I pipeline.
Primary Strategy:
- • Deep dive into metabolome
- • Concentration of minor metabolites
- • Fractionanation to simplified pools for testing
- • High rate of structured novelty
- • Priority driven by biological activity (IP created)
- • Potential to go directly to the organism
Derivative strategy:
- • Modify major metabolites
- • Novel chemistry creates IP positions
- • Abundant by-product compounds
- • One-step chemistry transforms ADME properties
- • Available for broad screening as pure compounds
- • Synthetic GMP (IP creates)
Two-prong strategy to explore pharmaceutical potential
Unprecedented Bias-Free Access to the Microbiome
that is Relevant to Human Health
Combining Novel Chemistry from the
Microbiome with Deep Analytics
RAPID AND STREAMLINED APPROACH
614-636-4850
